Editas Medicine (EDIT)
Market Price (9/5/2026): $3.19 | Market Cap: $380.5 MilSector: Health Care | Industry: Biotechnology
Editas Medicine (EDIT)
Market Price (9/5/2026): $3.19Market Cap: $380.5 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -51% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, and Targeted Therapies. | Weak multi-year price returns2Y Excs Rtn is -50%, 3Y Excs Rtn is -135% Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 14.59 | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -83 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -178% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 18% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -255%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -256% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -23% Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 21% Key risksEDIT key risks include [1] significant technical and regulatory hurdles for its unproven in vivo gene-editing approach, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -51% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, and Targeted Therapies. |
| Weak multi-year price returns2Y Excs Rtn is -50%, 3Y Excs Rtn is -135% |
| Meaningful short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 14.59 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -83 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -178% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 18% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -255%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -256% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -23% |
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 21% |
| Key risksEDIT key risks include [1] significant technical and regulatory hurdles for its unproven in vivo gene-editing approach, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Editas Medicine (EDIT) stock has lost about 5% since 5/31/2026 because of the following key factors:
1. Significant Share Dilution from May 2026 Public Offering.
Editas Medicine completed a public offering of common stock and warrants in May 2026, raising $125.0 million in gross proceeds. This offering led to a substantial increase in weighted-average common shares by approximately 41%, rising to 119.3 million in fiscal Q2 2026 (ended June 30, 2026) from 84.4 million a year earlier, thereby diluting the per-share value for existing shareholders.
2. Continued Net Losses Despite Improved Fiscal Q2 2026 Results.
While Editas Medicine reported a narrower net loss of $18.2 million, or $0.15 per share, in fiscal Q2 2026, beating analyst estimates and improving from a $53.2 million net loss a year prior, the company remains unprofitable. This improved financial performance was primarily driven by the recognition of deferred revenue from a collaboration with Bristol Myers Squibb and a $1.3 million restructuring benefit, rather than sustained core operational profitability.
Show more
Editas Medicine (EDIT) stock has lost about 5% since 5/31/2026 because of the following key factors:
1. Significant Share Dilution from May 2026 Public Offering.
Editas Medicine completed a public offering of common stock and warrants in May 2026, raising $125.0 million in gross proceeds. This offering led to a substantial increase in weighted-average common shares by approximately 41%, rising to 119.3 million in fiscal Q2 2026 (ended June 30, 2026) from 84.4 million a year earlier, thereby diluting the per-share value for existing shareholders.
2. Continued Net Losses Despite Improved Fiscal Q2 2026 Results.
While Editas Medicine reported a narrower net loss of $18.2 million, or $0.15 per share, in fiscal Q2 2026, beating analyst estimates and improving from a $53.2 million net loss a year prior, the company remains unprofitable. This improved financial performance was primarily driven by the recognition of deferred revenue from a collaboration with Bristol Myers Squibb and a $1.3 million restructuring benefit, rather than sustained core operational profitability.
3. Increased Research and Development Expenses for Distant Pipeline Milestones.
Research and development expenses increased by $4.0 million, or 25% year-over-year, to $20.2 million in fiscal Q2 2026. This increase was primarily due to higher external expenses supporting the preclinical and ongoing research for the EDIT-401 program. This increased cash burn, coupled with the long development timelines inherent in gene editing and initial data for EDIT-401 not expected until fiscal Q1 2027, can weigh on investor sentiment due to the capital-intensive nature and distant commercialization prospects.
Show less
Stock Movement Drivers
Fundamental Drivers
The -6.6% change in EDIT stock from 5/31/2026 to 9/4/2026 was primarily driven by a -18.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 5312026 | 9042026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.46 | 3.23 | -6.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 39 | 47 | 21.5% |
| P/S Multiple | 8.8 | 8.2 | -6.3% |
| Shares Outstanding (Mil) | 98 | 119 | -18.0% |
| Cumulative Contribution | -6.6% |
Market Drivers
5/31/2026 to 9/4/2026| Return | Correlation | |
|---|---|---|
| EDIT | -6.6% | |
| Market (SPY) | 1.8% | 23.6% |
| Sector (XLV) | 14.7% | 28.2% |
Fundamental Drivers
The 46.8% change in EDIT stock from 2/28/2026 to 9/4/2026 was primarily driven by a 91.8% change in the company's P/S Multiple.| (LTM values as of) | 2282026 | 9042026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.20 | 3.23 | 46.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 46 | 47 | 1.3% |
| P/S Multiple | 4.3 | 8.2 | 91.8% |
| Shares Outstanding (Mil) | 90 | 119 | -24.5% |
| Cumulative Contribution | 46.8% |
Market Drivers
2/28/2026 to 9/4/2026| Return | Correlation | |
|---|---|---|
| EDIT | 46.8% | |
| Market (SPY) | 12.6% | 34.3% |
| Sector (XLV) | 7.5% | 31.8% |
Fundamental Drivers
The 25.7% change in EDIT stock from 8/31/2025 to 9/4/2026 was primarily driven by a 47.0% change in the company's P/S Multiple.| (LTM values as of) | 8312025 | 9042026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.57 | 3.23 | 25.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 39 | 47 | 20.8% |
| P/S Multiple | 5.6 | 8.2 | 47.0% |
| Shares Outstanding (Mil) | 84 | 119 | -29.2% |
| Cumulative Contribution | 25.7% |
Market Drivers
8/31/2025 to 9/4/2026| Return | Correlation | |
|---|---|---|
| EDIT | 25.7% | |
| Market (SPY) | 20.4% | 31.9% |
| Sector (XLV) | 26.4% | 28.8% |
Fundamental Drivers
The -63.7% change in EDIT stock from 8/31/2023 to 9/4/2026 was primarily driven by a -75.1% change in the company's P/S Multiple.| (LTM values as of) | 8312023 | 9042026 | Change |
|---|---|---|---|
| Stock Price ($) | 8.91 | 3.23 | -63.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 19 | 47 | 143.3% |
| P/S Multiple | 32.9 | 8.2 | -75.1% |
| Shares Outstanding (Mil) | 71 | 119 | -40.2% |
| Cumulative Contribution | -63.7% |
Market Drivers
8/31/2023 to 9/4/2026| Return | Correlation | |
|---|---|---|
| EDIT | -63.7% | |
| Market (SPY) | 77.1% | 31.4% |
| Sector (XLV) | 34.7% | 28.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| EDIT Return | -62% | -67% | 14% | -87% | 61% | 50% | -96% |
| Peers Return | 26% | -27% | 2% | -33% | 2% | 16% | -25% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 13% | 106% |
Monthly Win Rates [3] | |||||||
| EDIT Win Rate | 17% | 33% | 50% | 17% | 67% | 67% | |
| Peers Win Rate | 43% | 42% | 50% | 40% | 57% | 60% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 56% | |
Max Drawdowns [4] | |||||||
| EDIT Max Drawdown | -71% | -70% | -46% | -89% | -69% | -34% | |
| Peers Max Drawdown | -35% | -49% | -40% | -53% | -51% | -32% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: NTLA, BEAM, VRTX, CRBU, REGN. See EDIT Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/4/2026 (YTD)
How Low Can It Go
| Event | EDIT | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -69.4% | -18.8% |
| % Gain to Breakeven | 226.5% | 23.1% |
| Time to Breakeven | 105 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -27.8% | -9.5% |
| % Gain to Breakeven | 38.6% | 10.5% |
| Time to Breakeven | 15 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -36.3% | -6.7% |
| % Gain to Breakeven | 57.1% | 7.1% |
| Time to Breakeven | 27 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -43.9% | -33.7% |
| % Gain to Breakeven | 78.4% | 50.9% |
| Time to Breakeven | 56 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -39.8% | -19.2% |
| % Gain to Breakeven | 66.1% | 23.8% |
| Time to Breakeven | 343 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -10.5% | -3.7% |
| % Gain to Breakeven | 11.7% | 3.9% |
| Time to Breakeven | 6 days | 6 days |
In The Past
Editas Medicine's stock fell -69.4% during the 2025 US Tariff Shock. Such a loss loss requires a 226.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | EDIT | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -69.4% | -18.8% |
| % Gain to Breakeven | 226.5% | 23.1% |
| Time to Breakeven | 105 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -27.8% | -9.5% |
| % Gain to Breakeven | 38.6% | 10.5% |
| Time to Breakeven | 15 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -36.3% | -6.7% |
| % Gain to Breakeven | 57.1% | 7.1% |
| Time to Breakeven | 27 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -43.9% | -33.7% |
| % Gain to Breakeven | 78.4% | 50.9% |
| Time to Breakeven | 56 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -39.8% | -19.2% |
| % Gain to Breakeven | 66.1% | 23.8% |
| Time to Breakeven | 343 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -29.6% | -12.2% |
| % Gain to Breakeven | 42.1% | 13.9% |
| Time to Breakeven | 10 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -29.6% | -6.8% |
| % Gain to Breakeven | 42.1% | 7.3% |
| Time to Breakeven | 10 days | 15 days |
In The Past
Editas Medicine's stock fell -69.4% during the 2025 US Tariff Shock. Such a loss loss requires a 226.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Editas Medicine (EDIT)
Editas Medicine (EDIT) is a clinical-stage biotechnology company dedicated to developing transformative genomic medicines using its proprietary gene editing platform, primarily based on CRISPR technology. The company's core focus is on precisely editing genes to correct the underlying genetic causes of a range of serious diseases, aiming to provide novel therapeutic solutions where current treatments are insufficient.
The company's pipeline features several key product candidates. EDIT-101 is currently in Phase 1/2 clinical trials for Leber Congenital Amaurosis 10, a leading cause of inherited childhood blindness. They are also developing EDIT-102 for other retinal conditions like Usher Syndrome 2A and autosomal dominant retinitis pigmentosa. Beyond ocular disorders, Editas is advancing EDIT-301 to address severe blood disorders such as sickle cell disease and transfusion-dependent beta-thalassemia.
Additionally, Editas Medicine is exploring the application of gene-edited immune cell therapies, including Natural Killer cell, alpha-beta T cell, and gamma delta T cell medicines, for various solid tumor cancers and other malignancies. The company strategically collaborates with pharmaceutical partners like Allergan and Juno Therapeutics to broaden its research and development scope. Editas primarily serves patients with severe genetic and oncological diseases, offering potential breakthrough treatments for conditions with high unmet medical needs.
AI Analysis | Feedback
Moderna for genetic diseases, but using CRISPR gene-editing technology.
An early-stage Intel for the human genome, building foundational CRISPR tools to repair DNA.
The Adobe of human DNA, developing powerful CRISPR tools to precisely edit and correct disease-causing genes.
AI Analysis | Feedback
- EDIT-101: A gene-editing therapy in clinical trials for Leber Congenital Amaurosis 10, an inherited childhood blindness.
- EDIT-102: A gene-editing therapy in development for Usher Syndrome 2A and autosomal dominant retinitis pigmentosa, both affecting vision and sometimes hearing.
- EDIT-301: A gene-editing therapy designed to treat sickle cell disease and transfusion-dependent beta-thalassemia.
- Gene-edited Natural Killer (NK) cell medicines: Therapies under development that modify NK cells to treat solid tumor cancers.
- Alpha-beta T cell therapies: Gene-edited T cell therapies being developed for various cancers.
- Gamma delta T cell therapies: Gene-edited T cell therapies in development for treating different types of cancer.
- Neurological disease therapy (Early Discovery): A therapy in early discovery stages aimed at treating a specific neurological disease.
AI Analysis | Feedback
Editas Medicine (EDIT) is a clinical-stage genome editing company focused on developing genomic medicines. As such, it does not currently sell approved products directly to individuals (patients). Instead, its primary "customers" are other companies with which it forms strategic alliances and research collaborations for the development and potential commercialization of its therapies. These collaborations often involve upfront payments, milestone payments, and future royalties, which represent Editas Medicine's revenue streams from these partners.
Based on the provided information, Editas Medicine's major corporate partners (customers) include:
- Juno Therapeutics, Inc.
- Allergan Pharmaceuticals International Limited
- Asklepios BioPharmaceutical, Inc. (AskBio)
AI Analysis | Feedback
AI Analysis | Feedback
Gilmore O'Neill, President and Chief Executive Officer
Gilmore O'Neill joined Editas Medicine as President and Chief Executive Officer in June 2022. He brings over 20 years of experience in genetic medicine, neurobiology, and clinical development. Prior to Editas, Dr. O'Neill served as Executive Vice President of Research & Development and Chief Medical Officer at Sarepta Therapeutics from 2018 to 2021. He also spent 15 years at Biogen, where his roles included Senior Vice President, Late Stage Clinical Development. He has a track record of driving successful clinical programs and achieving marketing approvals for several medicines, including Amondys®, Vyondys®, Spinraza®, Plegridy®, and Tecfidera®. He currently serves as a Director at Unity Biotechnology.
Amy Parison, Chief Financial Officer
Amy Parison was appointed Chief Financial Officer of Editas Medicine in March 2025, succeeding Erick J. Lucera. She joined Editas Medicine in August 2022 and has held multiple roles of increasing responsibility within the company, including Senior Vice President of Finance, Vice President of Finance, and Corporate Controller. Prior to her tenure at Editas, Ms. Parison was the Corporate Controller at Rubius Therapeutics, Inc., and held various financial roles at Vertex Pharmaceuticals.
Linda C. Burkly, Ph.D., Chief Scientific Officer
Linda C. Burkly joined Editas Medicine as Chief Scientific Officer in July 2023. She is responsible for leading the company's drug discovery team and activities across all therapeutic areas. Dr. Burkly brings more than 35 years of experience in biotechnology as a research leader, with expertise spanning drug discovery and development in immunological, neurological, and rare genetic disorders. She spent 37 years at Biogen, where she contributed to the foundations of approved medicines and late-stage programs, including the multiple sclerosis treatment Tysabri.
Brieana Buckley, Senior Vice President, Development and Program Leadership
Brieana Buckley serves as the Senior Vice President, Development and Program Leadership at Editas Medicine. She is a member of the executive leadership team responsible for advancing the company's experimental medicines.
Frank Panaccio, Senior Vice President and Chief Business Officer
Frank Panaccio is the Senior Vice President and Chief Business Officer at Editas Medicine. He is part of the executive leadership team responsible for business development and strategic initiatives for the company.
AI Analysis | Feedback
- Clinical Development and Regulatory Approval Risk: As a clinical-stage genome editing company, Editas Medicine's success is critically dependent on the successful outcome of its ongoing and future clinical trials for drug candidates such as EDIT-101, EDIT-102, and EDIT-301. Failure to achieve favorable results in these trials, significant delays, or unforeseen safety concerns would severely impact the company's ability to develop and commercialize its medicines. Even with successful clinical data, there is a substantial risk of not obtaining the necessary regulatory approvals from health authorities for these novel gene editing therapies.
- Intellectual Property and Patent Disputes: Editas Medicine's proprietary gene editing platform is based on CRISPR technology. The field of CRISPR technology is characterized by complex and often contentious intellectual property landscape, with numerous ongoing patent disputes and litigation among various entities. The company's ability to operate, develop, and commercialize its products hinges on its ability to maintain and defend its intellectual property rights and navigate potential challenges from competitors regarding patent infringement or ownership.
AI Analysis | Feedback
AI Analysis | Feedback
Addressable Markets for Editas Medicine's Main Products
Editas Medicine, Inc. focuses on developing genomic medicines for serious diseases. The addressable markets for their main products and services are as follows:
- Leber Congenital Amaurosis 10 (LCA10) - EDIT-101: The global market for Leber Congenital Amaurosis is estimated to be valued at approximately USD 1.29 billion in 2025 and is projected to reach USD 1.78 billion by 2032. North America is expected to account for an estimated 39.8% of this market in 2025. EDIT-101 specifically targets the IVS26 CEP290 mutation, which affects about 1,500 patients in the U.S.
- Usher Syndrome 2A - EDIT-102: The global Usher Syndrome market is estimated to be valued at approximately USD 2.29 billion in 2025 and is expected to reach USD 3.20 billion by 2032. North America is projected to lead this market, holding a 38.2% share in 2025. More specifically for Usher Syndrome Type 2, the global market size was valued at USD 1.35 billion in 2024 and is expected to reach USD 2.15 billion by 2032, with North America dominating at approximately 39.6% of the global market share in 2025.
- Autosomal Dominant Retinitis Pigmentosa: The global Retinitis Pigmentosa market size is projected to grow from approximately USD 14.27 billion in 2024 to USD 30.69 billion by 2035. In 2022, between 82,500 and 110,000 individuals in the United States were affected by retinitis pigmentosa. The total Retinitis Pigmentosa treatment market size in the U.S. was estimated to be nearly USD 260 million in 2023. Autosomal dominant retinitis pigmentosa accounts for 20-25% of nonsyndromic retinitis pigmentosa cases.
- Sickle Cell Disease - EDIT-301: The global sickle cell disease treatment market size was estimated at approximately USD 2.75 billion in 2023 and is projected to reach USD 7.42 billion by 2030. Other estimates place the global market size at USD 3.94 billion in 2025, reaching USD 20.47 billion by 2034. North America dominated the global market with a 37.87% share in 2023, and the United States alone held a 63.35% market share in 2025.
- Transfusion-Dependent Beta-Thalassemia - EDIT-301: The global thalassemia market size was valued at approximately USD 850.0 million in 2023 and is projected to grow at a CAGR of 7.8% from 2024 to 2030. The beta-thalassemia segment constituted 71.2% of the revenue share in 2023, and its market size is expected to reach USD 822.5 million by 2034 from USD 340.3 million in 2023. North America held the largest share of the global thalassemia market, at 42.8% in 2023.
- Gene-Edited Natural Killer (NK) Cell Medicines for Solid Tumor Cancers: The global natural killer (NK) cell therapeutics market size was estimated at USD 340.25 million in 2024 and is predicted to increase to approximately USD 9,997.65 million by 2034. The cancer segment held the largest share in the NK cell therapeutics market in 2024. The CAR-NK cell therapy market was valued at USD 2.16 billion in 2024 and is projected to reach USD 3.10 billion by 2032, with the U.S. currently dominating.
- Alpha-Beta T Cells for Multiple Cancers: The global T-cell immunotherapy market size was approximately USD 8.43 billion in 2025 and is predicted to increase to USD 26.53 billion by 2034. Another estimate places the T-cell immunotherapy market at USD 3.94 billion in 2025, rising to USD 32.75 billion by 2030. North America held the largest share of the T-cell therapy market, at 63.88% in 2022. The cancer gene therapy market, which includes T-cell therapies, was valued at USD 24.96 billion in 2025 and is estimated to grow to USD 67.11 billion by 2031, with solid tumors projected to advance at a 27.29% CAGR between 2026 and 2031.
- Gamma Delta T Cell Therapies to Treat Cancer: The gamma delta T cell cancer therapy market size was USD 2.11 billion in 2025 and is projected to reach USD 4.94 billion by 2030. North America was the largest region in this market in 2025.
- Therapy to Treat a Neurological Disease (Early Discovery Program): The gene therapy market for neurological diseases was valued at USD 3.13 billion in 2024 and is expected to grow to USD 5.76 billion in 2029. The Gene Therapy in CNS Disorder Market is projected to reach USD 13.86 billion by 2025 and USD 191.04 billion by 2035. The United States is a leading region for gene therapy in CNS disorders.
AI Analysis | Feedback
AI Analysis | Feedback
Capital Allocation Decisions (2021-2025)
Share Issuance
- Editas Medicine generated $17.3 million in proceeds from sales of common stock under an at-the-market (ATM) facility after September 30, 2025.
- As of February 27, 2026, the company had 97,871,999 shares of common stock outstanding.
Inbound Investments
- Collaboration and other research and development revenues increased to $40.5 million for the full year 2025, up from $32.3 million in 2024. This increase was primarily due to the recognition of deferred revenue from a concluded collaboration agreement with a strategic partner and a milestone achieved in 2025 under a collaboration with Bristol Myers Squibb (BMS).
- In the third quarter of 2025, the company recognized $7.5 million in collaboration and other research and development revenues, largely attributed to a milestone payment from its agreement with Bristol Myers Squibb.
- A milestone payment was triggered in the second quarter of 2025 from the collaboration agreement with Bristol Myers Squibb, following the acceptance of the first Investigational New Drug (IND)/Clinical Trial Application (CTA) for the CD19 HD Allo CAR T program.
Outbound Investments
- Editas Medicine has made one investment in Nomad Health.
- The company has not made any acquisitions.
Capital Expenditures
- Editas Medicine expects its existing cash, cash equivalents, and marketable securities to fund its operating expenses and capital expenditure requirements into the third quarter of 2027.
- Capital expenditures are an ongoing requirement for the company, supporting the advancement of its in vivo gene editing programs, including lead candidate EDIT-401, through preclinical and clinical development.
Peer Outperformance in Biotechnology
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 7 | 13.9% | 96.3% | 127.8% | CAH 414% · MCK 351% · COR 179% |
| Managed Health Care | 8 | 33.2% | 1.7% | 3.3% | OSCR 77% · HQY 48% · ELV 16% |
| Health Care Services | 20 | 21.0% | 52.1% | -1.5% | HIMS 238% · RDNT 134% · DGX 68% |
| Health Care Facilities | 24 | 1.8% | 4.9% | -19.0% | THC 249% · NHC 244% · ENSG 108% |
| Health Care Equipment | 50 | -5.3% | -4.8% | -24.0% | POCI 10775% · UFPT 318% · GKOS 200% |
| Health Care Supplies | 12 | 32.3% | -14.4% | -35.5% | LNTH 272% · HAE 59% · MMSI 23% |
| Pharmaceuticals | 63 | -0.9% | 0.6% | -36.4% | LQDA 2406% · INDV 1148% · ETON 1022% |
| Life Sciences Tools & Services | 109 | 2.4% | -28.7% | -73.9% | SNWV 1688% · MEDP 203% · AXGN 178% |
| Biotechnology ← | 363 | 8.8% | -25.7% | -76.8% | BRTX 73900% · DNTH 1558% · CELZ 1486% |
| Health Care Technology | 20 | -25.0% | -56.7% | -78.6% | SPOK 68% · HSTM -2% · VEEV -13% |
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 21.20 |
| Mkt Cap | 2.4 |
| Rev LTM | 108 |
| Op Inc LTM | -96 |
| FCF LTM | -108 |
| FCF 3Y Avg | -144 |
| CFO LTM | -108 |
| CFO 3Y Avg | -139 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 11.4% |
| Rev Chg 3Y Avg | 16.6% |
| Rev Chg Q | -15.7% |
| QoQ Delta Rev Chg LTM | -0.9% |
| Op Inc Chg LTM | 23.4% |
| Op Inc Chg 3Y Avg | 1.4% |
| Op Mgn LTM | -209.9% |
| Op Mgn 3Y Avg | -323.9% |
| QoQ Delta Op Mgn LTM | -7.9% |
| CFO/Rev LTM | -242.7% |
| CFO/Rev 3Y Avg | -309.9% |
| FCF/Rev LTM | -247.7% |
| FCF/Rev 3Y Avg | -318.6% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 2.4 |
| P/S | 13.4 |
| P/Op Inc | -2.7 |
| P/EBIT | -2.7 |
| P/E | -2.9 |
| P/CFO | -2.4 |
| Total Yield | -11.0% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -19.2% |
| D/E | 0.0 |
| Net D/E | -0.3 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 11.1% |
| 3M Rtn | 10.0% |
| 6M Rtn | 10.5% |
| 12M Rtn | 32.9% |
| 3Y Rtn | -30.9% |
| 1M Excs Rtn | 10.0% |
| 3M Excs Rtn | 5.5% |
| 6M Excs Rtn | -4.0% |
| 12M Excs Rtn | 14.2% |
| 3Y Excs Rtn | -103.1% |
Comparison Analyses
Price Behavior
| Market Price | $3.23 | |
| Market Cap ($ Bil) | 0.4 | |
| First Trading Date | 02/03/2016 | |
| Distance from 52W High | -22.2% | |
| 50 Days | 200 Days | |
| DMA Price | $3.00 | $2.61 |
| DMA Trend | down | up |
| Distance from DMA | 7.5% | 23.9% |
| 3M | 1YR | |
| Volatility | 73.5% | 84.7% |
| Downside Capture | 23.30 | 178.59 |
| Upside Capture | 98.98 | 170.89 |
| Correlation (SPY) | 26.4% | 32.2% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 2.99 | 1.14 | 1.50 | 2.21 | 2.16 | 2.10 |
| Up Beta | 0.31 | 1.02 | 2.48 | 2.95 | 2.54 | 2.01 |
| Down Beta | 6.60 | 1.56 | 2.54 | 2.53 | 2.63 | 1.83 |
| Up Capture | 507% | 65% | 36% | 250% | 250% | 934% |
| Bmk +ve Days | 10 | 21 | 32 | 68 | 138 | 427 |
| Stock +ve Days | 11 | 17 | 28 | 61 | 116 | 323 |
| Down Capture | 303% | 150% | 103% | 148% | 148% | 113% |
| Bmk -ve Days | 11 | 21 | 32 | 59 | 113 | 324 |
| Stock -ve Days | 10 | 23 | 34 | 61 | 126 | 410 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with EDIT | |
|---|---|---|---|---|
| EDIT | 28.3% | 84.7% | 0.66 | - |
| Sector ETF (XLV) | 26.5% | 16.0% | 1.28 | 28.8% |
| Equity (SPY) | 19.7% | 12.8% | 1.13 | 31.9% |
| Gold (GLD) | 24.6% | 29.2% | 0.75 | 26.4% |
| Commodities (DBC) | 44.1% | 20.4% | 1.69 | -9.1% |
| Real Estate (VNQ) | 9.1% | 13.6% | 0.39 | 16.7% |
| Bitcoin (BTCUSD) | -26.9% | 43.8% | -0.59 | 31.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with EDIT | |
|---|---|---|---|---|
| EDIT | -45.2% | 93.5% | -0.24 | - |
| Sector ETF (XLV) | 6.6% | 15.1% | 0.25 | 31.6% |
| Equity (SPY) | 12.8% | 17.2% | 0.57 | 38.1% |
| Gold (GLD) | 19.1% | 18.8% | 0.82 | 10.1% |
| Commodities (DBC) | 10.7% | 19.5% | 0.43 | 1.1% |
| Real Estate (VNQ) | 1.7% | 18.9% | -0.01 | 33.2% |
| Bitcoin (BTCUSD) | 10.6% | 52.6% | 0.38 | 27.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with EDIT | |
|---|---|---|---|---|
| EDIT | -15.9% | 84.0% | 0.16 | - |
| Sector ETF (XLV) | 10.8% | 16.7% | 0.53 | 32.9% |
| Equity (SPY) | 15.3% | 17.9% | 0.72 | 37.7% |
| Gold (GLD) | 12.4% | 16.3% | 0.62 | 7.6% |
| Commodities (DBC) | 7.9% | 18.1% | 0.35 | 8.4% |
| Real Estate (VNQ) | 4.8% | 20.7% | 0.19 | 26.8% |
| Bitcoin (BTCUSD) | 64.0% | 66.2% | 1.04 | 18.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 9/5/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/5/2026 | 5.5% | 3.3% | 12.0% |
| 5/5/2026 | 1.3% | 2.0% | -7.3% |
| 3/9/2026 | 16.0% | 22.0% | 37.0% |
| 11/10/2025 | 2.0% | 5.3% | 5.3% |
| 8/12/2025 | 34.5% | 14.8% | 18.3% |
| 5/12/2025 | -2.6% | -3.2% | 31.8% |
| 3/5/2025 | -13.2% | -26.3% | -45.4% |
| 1/13/2025 | -7.9% | -3.2% | -6.3% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 17 | 15 | 11 |
| # Negative | 8 | 10 | 14 |
| Median Positive | 9.4% | 7.2% | 23.8% |
| Median Negative | -8.9% | -11.9% | -16.7% |
| Max Positive | 34.5% | 45.1% | 58.3% |
| Max Negative | -13.2% | -26.3% | -45.4% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/5/2026 | 5.5% | 3.3% | 12.0% |
| 5/5/2026 | 1.3% | 2.0% | -7.3% |
| 3/9/2026 | 16.0% | 22.0% | 37.0% |
| 11/10/2025 | 2.0% | 5.3% | 5.3% |
| 8/12/2025 | 34.5% | 14.8% | 18.3% |
| 5/12/2025 | -2.6% | -3.2% | 31.8% |
| 3/5/2025 | -13.2% | -26.3% | -45.4% |
| 1/13/2025 | -7.9% | -3.2% | -6.3% |
| 11/4/2024 | -1.0% | 7.2% | -32.0% |
| 8/7/2024 | -12.2% | -14.7% | -25.4% |
| 5/8/2024 | -11.4% | 0.0% | -4.4% |
| 2/28/2024 | 24.9% | 3.2% | -16.0% |
| 11/3/2023 | 18.2% | 11.9% | 57.2% |
| 8/2/2023 | 5.7% | 2.9% | 4.5% |
| 5/5/2023 | 12.0% | 9.6% | 8.3% |
| 2/22/2023 | 6.2% | -1.5% | -20.5% |
| 11/2/2022 | 1.1% | -12.0% | -21.1% |
| 8/3/2022 | 13.4% | 9.2% | -10.8% |
| 5/4/2022 | 11.5% | -20.6% | -18.6% |
| 2/24/2022 | 10.1% | 19.0% | 31.5% |
| 11/8/2021 | 8.2% | 1.1% | -17.4% |
| 8/4/2021 | 9.4% | 45.1% | 58.3% |
| 5/5/2021 | 0.2% | -5.4% | -3.8% |
| 2/25/2021 | -9.9% | -13.2% | -15.1% |
| 11/5/2020 | -3.4% | -11.9% | 23.8% |
| SUMMARY STATS | |||
| # Positive | 17 | 15 | 11 |
| # Negative | 8 | 10 | 14 |
| Median Positive | 9.4% | 7.2% | 23.8% |
| Median Negative | -8.9% | -11.9% | -16.7% |
| Max Positive | 34.5% | 45.1% | 58.3% |
| Max Negative | -13.2% | -26.3% | -45.4% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/05/2026 | 10-Q |
| 03/31/2026 | 05/05/2026 | 10-Q |
| 12/31/2025 | 03/09/2026 | 10-K |
| 09/30/2025 | 11/10/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/12/2025 | 10-Q |
| 12/31/2024 | 03/05/2025 | 10-K |
| 09/30/2024 | 11/04/2024 | 10-Q |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 02/28/2024 | 10-K |
| 09/30/2023 | 11/03/2023 | 10-Q |
| 06/30/2023 | 08/02/2023 | 10-Q |
| 03/31/2023 | 05/05/2023 | 10-Q |
| 12/31/2022 | 02/22/2023 | 10-K |
| 09/30/2022 | 11/02/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/05/2026 | 10-Q |
| 03/31/2026 | 05/05/2026 | 10-Q |
| 12/31/2025 | 03/09/2026 | 10-K |
| 09/30/2025 | 11/10/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/12/2025 | 10-Q |
| 12/31/2024 | 03/05/2025 | 10-K |
| 09/30/2024 | 11/04/2024 | 10-Q |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/08/2024 | 10-Q |
| 12/31/2023 | 02/28/2024 | 10-K |
| 09/30/2023 | 11/03/2023 | 10-Q |
| 06/30/2023 | 08/02/2023 | 10-Q |
| 03/31/2023 | 05/05/2023 | 10-Q |
| 12/31/2022 | 02/22/2023 | 10-K |
| 09/30/2022 | 11/02/2022 | 10-Q |
| 06/30/2022 | 08/03/2022 | 10-Q |
| 03/31/2022 | 05/04/2022 | 10-Q |
| 12/31/2021 | 02/24/2022 | 10-K |
| 09/30/2021 | 11/09/2021 | 10-Q |
| 06/30/2021 | 08/05/2021 | 10-Q |
| 03/31/2021 | 05/06/2021 | 10-Q |
| 12/31/2020 | 02/26/2021 | 10-K |
| 09/30/2020 | 11/06/2020 | 10-Q |
| 06/30/2020 | 08/07/2020 | 10-Q |
| 03/31/2020 | 05/08/2020 | 10-Q |
| 12/31/2019 | 02/26/2020 | 10-K |
| 09/30/2019 | 11/12/2019 | 10-Q |
Insider Activity
Updated 9/4/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Parison, Amy | SVP, Chief Financial Officer | Direct | Sell | 9042026 | 3.04 | 453 | 1,376 | 42,032 | Form |
| 2 | Burkly, Linda | EVP, CHIEF SCIENTIFIC OFFICER | Direct | Sell | 9042026 | 3.04 | 709 | 2,153 | 187,274 | Form |
| 3 | O'Neill, Gilmore Neil | CEO | Direct | Sell | 9042026 | 3.04 | 5,124 | 15,563 | 738,614 | Form |
| 4 | Parison, Amy | SVP, Chief Financial Officer | Direct | Sell | 8052026 | 2.58 | 678 | 1,749 | 36,873 | Form |
| 5 | Burkly, Linda | EVP, CHIEF SCIENTIFIC OFFICER | Direct | Sell | 7292026 | 2.67 | 4,928 | 13,158 | 166,525 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Parison, Amy | SVP, Chief Financial Officer | Direct | Sell | 9042026 | 3.04 | 453 | 1,376 | 42,032 | Form |
| 2 | Burkly, Linda | EVP, CHIEF SCIENTIFIC OFFICER | Direct | Sell | 9042026 | 3.04 | 709 | 2,153 | 187,274 | Form |
| 3 | O'Neill, Gilmore Neil | CEO | Direct | Sell | 9042026 | 3.04 | 5,124 | 15,563 | 738,614 | Form |
| 4 | Parison, Amy | SVP, Chief Financial Officer | Direct | Sell | 8052026 | 2.58 | 678 | 1,749 | 36,873 | Form |
| 5 | Burkly, Linda | EVP, CHIEF SCIENTIFIC OFFICER | Direct | Sell | 7292026 | 2.67 | 4,928 | 13,158 | 166,525 | Form |
| 6 | Parison, Amy | SVP, Chief Financial Officer | Direct | Sell | 6052026 | 2.70 | 464 | 1,253 | 40,434 | Form |
| 7 | O'Neill, Gilmore Neil | CEO | Direct | Sell | 6052026 | 2.70 | 15,380 | 41,543 | 670,718 | Form |
| 8 | Burkly, Linda | EVP, CHIEF SCIENTIFIC OFFICER | Direct | Sell | 6052026 | 2.70 | 731 | 1,975 | 181,776 | Form |
| 9 | O'Neill, Gilmore Neil | CEO | Direct | Sell | 3042026 | 2.02 | 5,394 | 10,894 | 532,581 | Form |
| 10 | Parison, Amy | SVP, Chief Financial Officer | Direct | Sell | 3042026 | 2.02 | 474 | 957 | 31,177 | Form |
| 11 | Burkly, Linda | EVP, CHIEF SCIENTIFIC OFFICER | Direct | Sell | 3042026 | 2.02 | 749 | 1,513 | 137,389 | Form |
| 12 | Burkly, Linda | EVP, CHIEF SCIENTIFIC OFFICER | Direct | Sell | 12042025 | 2.15 | 713 | 1,535 | 148,084 | Form |
| 13 | O'Neill, Gilmore Neil | CEO | Direct | Sell | 12042025 | 2.15 | 5,603 | 12,064 | 579,371 | Form |
| 14 | Parison, Amy | SVP, Chief Financial Officer | Direct | Sell | 12042025 | 2.15 | 461 | 993 | 34,252 | Form |
| 15 | Burkly, Linda | EVP, CHIEF SCIENTIFIC OFFICER | Direct | Sell | 9042025 | 2.60 | 710 | 1,843 | 180,403 | Form |
| 16 | Parison, Amy | SVP, Chief Financial Officer | Direct | Sell | 9042025 | 2.60 | 458 | 1,189 | 42,496 | Form |
| 17 | O'Neill, Gilmore Neil | CEO | Direct | Sell | 9042025 | 2.60 | 5,592 | 14,517 | 713,123 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.